CloudMD Announces Divestment of Primary Care Clinics and Cloud Practice to WELL Health
VANCOUVER, British Columbia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)...
Day: October 11, 2022
Nephros Announces Agreement to Sell Pathogen Detection Systems Business and Preliminary Results for Quarter Ended September 30, 2022
Sale Reduces Cash Burn, Includes Seven-Year Earn-Out Provision;Third Quarter Revenue Expected to be Approximately $2.5 Million; Active Customer Sites Increase...
Bass Pro and CorVel Named Risk Management Team of the Year by Business Insurance
US Insurance Award Recognizes Their Innovative Solution for Managing Return-to-Work and Temporary Total DisabilityFORT WORTH, Texas, Oct. 11, 2022 (GLOBE...
Aurora Spine Corporation to Attend the North American Spine Society (NASS) Annual Meeting
- Company to showcase products including recently FDA cleared SiLO TFXTM at booth #4604 – CARLSBAD, Calif., Oct. 11, 2022...
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
Eight Posters Highlighting Pre-Clinical Programs and Leading Gene Therapy Manufacturing and Administration CapabilitiesLEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 11,...
Syneos Health Expands Partnership with Datavant to Accelerate Delivery of New Therapies to Patients
Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for ClientsMORRISVILLE, N.C., Oct. 11, 2022...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data...
Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulins NovoLog® and Fiasp®
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE...
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7%...
Walden Biosciences Appoints Peter Guest Linde, M.D. as Chief Medical Officer
Experienced nephrologist brings extensive clinical leadership and industry expertise to drive transformational approaches to treating kidney diseasesCAMBRIDGE, Mass., Oct. 11,...